Sage Therapeutics — Q1 2025 Earnings Presentation
9 slides from Sage Therapeutics's earnings presentation, Apr 29, 2025
Slide 1: First Quarter 2025 Financial Results
First Quarter 2025 Financial Results April 29, 2025
Slide 2: Safe Harbor Statement
• Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements, − We may encounter unexpected safety or tolerability issues with respect to any of our product candidates or which may be identified by the use of words such as “may,” “migh
Slide 3: Sage Therapeutics call participants
Sage Therapeutics call participants Barry Greene Chris Benecchi Mike Quirk Chief Executive Officer Chief Operating Officer Chief Scientific Officer and Interim Head of R&D Sage Therapeutics © 2025 3
Slide 4: 2025 core priorities
2025 core priorities 1 2 3 Continued Targeted Financial Commercial Pipeline Focus Momentum Strategically invest in Develop novel programs in Optimize ZURZUVAE commercialization of diseases with high unmet need in commercialization in PPD, pipeline ZURZUVAE® in highly Neurodevelopmental Disorders & p
Slide 5: Executing on goal to establish ZURZUVAE as the standard of care for women with PPD
Executing on goal to establish ZURZUVAE as the standard of care for women with PPD >3,000 Shipments of ZURZUVAE to women with PPD in Q1 2025 ~80% >70% of prescriptions of women prescribed were written ZURZUVAE received by OBGYNs in it as their first new Q1 2025 treatment for PPD Please refer to the
Slide 6: 2025 commercialization initiatives underway
2025 commercialization initiatives underway SALESFORCE EXPANSION HCP & PATIENT WEBSITES Joint salesforce expansion to cover a 1 wider reach of HCPs who treat PPD 2 Build on ZURZUVAE branded media Expand social media influencer 3 campaigns/DTC Increase investment in disease state 4 awareness to suppo
Slide 7: First Quarter 2025 Financial Results
First Quarter 2025 Financial Results Item Q1 ‘25 Q1 ’24 Product revenue, net $0.0M $1.7M License and milestone revenue - related party $0.0M $0.0M Collaboration revenue - related party $13.8M $6.2M Other Collaboration revenue $0.2M $0.0M Total Revenue $14.1M $7.9M Cost of Revenues $0.7M $1.3M R&D Ex
Slide 8: Our pipeline
Our pipeline COMPOUND INDICATIONS PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 FDA APPROVED COLLABORATORS Neuropsychiatry ZURZUVAE®* Postpartum (zuranolone) Oral CIV Depression MARKETED Neurodevelopmental Disorders Behavioral symptoms SAGE-319 associated with PHASE 1 GABA Hypofunction neurodevelopmental dis
Slide 9: Q&A
Q&A Sage Therapeutics © 2025 9